Status:

COMPLETED

Combined PSMA PET/MRI for Detection of Lymph Node Metastases in High-risk Prostate Cancer Patients

Lead Sponsor:

Norwegian University of Science and Technology

Collaborating Sponsors:

St. Olavs Hospital

Haukeland University Hospital

Conditions:

Prostatic Neoplasms

Neoplasm Metastasis

Eligibility:

MALE

Phase:

NA

Brief Summary

For high-risk prostate cancer patients, detection of lymph node metastases is crucial to ensure optimal treatment. Standard treatment for these patients is radiotherapy or surgery. The surgery involv...

Detailed Description

High-risk prostate cancer patients have a high probability for lymph node metastases in the pelvic region. The lymph node status is an important prognostic factor in determining the risk of later rela...

Eligibility Criteria

Inclusion

  • Inclusion criteria (surgery cohort):
  • High risk localized/locally advanced prostate cancer patients who are candidates for radical prostatectomy plus bilateral extended PLND; ISUP Gleason grade group ≥ 4
  • Inclusion criteria (radiotherapy cohort):
  • High-risk localized/locally advanced prostate cancer patients scheduled for radiation treatment of the prostate and pelvic lymph nodes; ISUP Gleason grade group ≥ 4
  • Exclusion criteria (surgery and radiotherapy cohort):
  • Prior history of any other cancer the last 5 years excluding basal cell carcinoma
  • Proven metastases in bones or other distant metastases
  • General contra-indications for MRI (pacemaker, aneurysm clips, any form of metal in the body, severe claustrophobia)
  • Serious concomitant systemic disorders that in the opinion of the investigator would compromise the patient's ability to complete the study or interfere with the evaluation of the efficacy and safety of the study objectives
  • Metal implants in the pelvic region which will deteriorate PET/MR/CT image quality.

Exclusion

    Key Trial Info

    Start Date :

    April 28 2021

    Trial Type :

    INTERVENTIONAL

    Allocation :

    ACTUAL

    End Date :

    September 30 2024

    Estimated Enrollment :

    90 Patients enrolled

    Trial Details

    Trial ID

    NCT04790968

    Start Date

    April 28 2021

    End Date

    September 30 2024

    Last Update

    November 15 2024

    Active Locations (3)

    Enter a location and click search to find clinical trials sorted by distance.

    Page 1 of 1 (3 locations)

    1

    Haukeland University Hospital

    Bergen, Norway

    2

    University Hosptial of North Norway

    Tromsø, Norway

    3

    St Olavs Hospital, Trondheim University Hospital

    Trondheim, Norway

    Combined PSMA PET/MRI for Detection of Lymph Node Metastases in High-risk Prostate Cancer Patients | DecenTrialz